Skip to main content
Erschienen in: Strahlentherapie und Onkologie 9/2012

01.09.2012 | Original article

Long-term outcome after neoadjuvant radiochemotherapy in locally advanced noninflammatory breast cancer and predictive factors for a pathologic complete remission

Results of a multivariate analysis

verfasst von: C. Matuschek, PD Dr. E. Bölke, S.L. Roth, K. Orth, I. Lang, H. Bojar, J.W. Janni, W. Audretsch, C. Nestle-Kraemling, G. Lammering, V. Speer, S. Gripp, P.A. Gerber, B.A. Buhren, R. Sauer, M. Peiper, M. Schauer, M. Dommach, K. Struse-Soll, W. Budach

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 9/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

An earlier published series of neoadjuvant radiochemotherapy (NRT-CHX) in locally advanced noninflammatory breast cancer (LABC) has now been updated with a follow-up of more than 15 years. Long-term outcome data and predictive factors for pathologic complete response (pCR) were analyzed.

Patients and methods

During 1991–1998, 315 LABC patients (cT1-cT4/cN0-N1) were treated with NRT-CHX. Preoperative radiotherapy (RT) consisted of external beam radiation therapy (EBRT) of 50 Gy (5 × 2 Gy/week) to the breast and the supra-/infraclavicular lymph nodes combined with an electron boost in 214 cases afterwards or—in case of breast conservation—a 10-Gy interstitial boost with 192Ir afterloading before EBRT. Chemotherapy was administered prior to RT in 192 patients, and concomitantly in 113; 10 patients received no chemotherapy. The update of all follow-up ended in November 2011. Age, tumor grade, nodal status, hormone receptor status, simultaneous vs. sequential CHX, and the time interval between end of RT and surgery were examined in multivariate terms with pCR and overall survival as end point.

Results

The total pCR rate after neoadjuvant RT-CHX reached 29.2%, with LABC breast conservation becoming possible in 50.8% of cases. In initially node-positive cases (cN+), a complete nodal response (pN0) after NRT-CHX was observed in 56% (89/159). The multivariate analysis revealed that a longer time interval to surgery increased the probability for a pCR (HR 1.17 [95% CI 1.05–1.31], p < 0.01). However, in large tumors (T3–T4) a significantly reduced pCR rate (HR 0.89 [95% CI 0.80–0.99], p = 0.03) was obtained. Importantly, pCR was the strongest prognostic factor for long-term survival (HR 0.28 [95% CI 0.19–0.56], p < 0.001).

Conclusion

pCR identifies patients with a significantly better prognosis for long-term survival. However, a long time interval to surgery (> 2 months) increases the probability of pCR after NRT-CHX.
Literatur
1.
Zurück zum Zitat Roth SL, Audretsch W, Bojar H et al (2010) Retrospective study of neoadjuvant versus adjuvant radiochemotherapy in locally advanced noninflammatory breast cancer: survival advantage in cT2 category by neoadjuvant radiochemotherapy. Strahlenther Onkol 186:299–306PubMedCrossRef Roth SL, Audretsch W, Bojar H et al (2010) Retrospective study of neoadjuvant versus adjuvant radiochemotherapy in locally advanced noninflammatory breast cancer: survival advantage in cT2 category by neoadjuvant radiochemotherapy. Strahlenther Onkol 186:299–306PubMedCrossRef
2.
Zurück zum Zitat Hung WK, Lau Y, Chan CM, Yip AW (2000) Experience of neoadjuvant chemotherapy for breast cancer at a public hospital: retrospective study. Hong Kong Med J 6:265–268PubMed Hung WK, Lau Y, Chan CM, Yip AW (2000) Experience of neoadjuvant chemotherapy for breast cancer at a public hospital: retrospective study. Hong Kong Med J 6:265–268PubMed
3.
Zurück zum Zitat Jiralerspong S, Palla SL, Giordano SH et al (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27:3297–3302PubMedCrossRef Jiralerspong S, Palla SL, Giordano SH et al (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27:3297–3302PubMedCrossRef
4.
Zurück zum Zitat Fangberget A, Nilsen LB, Hole KH et al (2011) Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging. Eur Radiol 21:1188–1199PubMedCrossRef Fangberget A, Nilsen LB, Hole KH et al (2011) Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging. Eur Radiol 21:1188–1199PubMedCrossRef
5.
Zurück zum Zitat Wildiers H, Neven P, Christiaens MR et al (2011) Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer. Ann Oncol 22:588–594PubMedCrossRef Wildiers H, Neven P, Christiaens MR et al (2011) Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer. Ann Oncol 22:588–594PubMedCrossRef
6.
Zurück zum Zitat Audretsch W, Andree C (2012) Advancements in oncoplastic surgery of the breast. In: Babiera GV et al (eds) Advanced Therapy of Breast Disease, 3rd edn. PMPH, pp 613–642 Audretsch W, Andree C (2012) Advancements in oncoplastic surgery of the breast. In: Babiera GV et al (eds) Advanced Therapy of Breast Disease, 3rd edn. PMPH, pp 613–642
7.
Zurück zum Zitat Sataloff DM, Mason BA, Prestipino AJ et al (1995) Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180:297–306PubMed Sataloff DM, Mason BA, Prestipino AJ et al (1995) Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180:297–306PubMed
8.
9.
Zurück zum Zitat Minckwitz G von, Untch M, Nuesch E et al (2011) Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 125:145–156CrossRef Minckwitz G von, Untch M, Nuesch E et al (2011) Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 125:145–156CrossRef
10.
Zurück zum Zitat Mauriac L, Durand M, Avril A, Dilhuydy JM (1991) Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol 2:347–354PubMed Mauriac L, Durand M, Avril A, Dilhuydy JM (1991) Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol 2:347–354PubMed
11.
Zurück zum Zitat Fisher B, Bryant J, Wolmark N et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672–2685PubMed Fisher B, Bryant J, Wolmark N et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672–2685PubMed
12.
Zurück zum Zitat Scholl SM, Pierga JY, Asselain B et al (1995) Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 31A:1969–1975PubMedCrossRef Scholl SM, Pierga JY, Asselain B et al (1995) Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 31A:1969–1975PubMedCrossRef
13.
Zurück zum Zitat Shanta V, Swaminathan R, Rama R, Radhika R (2008) Retrospective analysis of locally advanced noninflammatory breast cancer from Chennai, South India, 1990–1999. Int J Radiat Oncol Biol Phys 70:51–58PubMedCrossRef Shanta V, Swaminathan R, Rama R, Radhika R (2008) Retrospective analysis of locally advanced noninflammatory breast cancer from Chennai, South India, 1990–1999. Int J Radiat Oncol Biol Phys 70:51–58PubMedCrossRef
14.
Zurück zum Zitat Lerouge D, Touboul E, Lefranc JP et al (2004) Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients. Int J Radiat Oncol Biol Phys 59:1062–1073PubMedCrossRef Lerouge D, Touboul E, Lefranc JP et al (2004) Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients. Int J Radiat Oncol Biol Phys 59:1062–1073PubMedCrossRef
15.
Zurück zum Zitat Carter CL, Allen C, Henson DE (1989) Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181–187PubMedCrossRef Carter CL, Allen C, Henson DE (1989) Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181–187PubMedCrossRef
16.
Zurück zum Zitat Koscielny S, Tubiana M, Le MG et al (1984) Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer 49:709–715PubMedCrossRef Koscielny S, Tubiana M, Le MG et al (1984) Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer 49:709–715PubMedCrossRef
17.
Zurück zum Zitat Withers HR, Thames HD (1988) Dose fractionation and volume effects in normal tissues and tumors. Am J Clin Oncol 11:313–329PubMedCrossRef Withers HR, Thames HD (1988) Dose fractionation and volume effects in normal tissues and tumors. Am J Clin Oncol 11:313–329PubMedCrossRef
18.
Zurück zum Zitat Bear HD, Anderson S, Smith RE et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019–2027PubMedCrossRef Bear HD, Anderson S, Smith RE et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019–2027PubMedCrossRef
19.
Zurück zum Zitat Rastogi P, Anderson SJ, Bear HD et al (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26:778–785PubMedCrossRef Rastogi P, Anderson SJ, Bear HD et al (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26:778–785PubMedCrossRef
20.
Zurück zum Zitat Fisher B, Dignam J, Wolmark N et al (1998) Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16:441–452PubMed Fisher B, Dignam J, Wolmark N et al (1998) Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16:441–452PubMed
21.
Zurück zum Zitat Dontu G, Liu S, Wicha MS (2005) Stem cells in mammary development and carcinogenesis: implications for prevention and treatment. Stem Cell Rev 1:207–213PubMedCrossRef Dontu G, Liu S, Wicha MS (2005) Stem cells in mammary development and carcinogenesis: implications for prevention and treatment. Stem Cell Rev 1:207–213PubMedCrossRef
22.
Zurück zum Zitat Hortobagyi GN, Ames FC, Buzdar AU et al (1988) Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62:2507–2516PubMedCrossRef Hortobagyi GN, Ames FC, Buzdar AU et al (1988) Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62:2507–2516PubMedCrossRef
23.
Zurück zum Zitat Audretsch W, Rezai M, Kolotas C et al (1994) Oncoplastic surgery: “Target” volume reduction, lumpectomy reconstruction and flap-supported operability in breast cancer. Proceedings 2nd European Congress on Senology, Vienna, Austria, October 2–6. Mendoza Bologna, Italy, pp 139–157 Audretsch W, Rezai M, Kolotas C et al (1994) Oncoplastic surgery: “Target” volume reduction, lumpectomy reconstruction and flap-supported operability in breast cancer. Proceedings 2nd European Congress on Senology, Vienna, Austria, October 2–6. Mendoza Bologna, Italy, pp 139–157
24.
Zurück zum Zitat Audretsch W, Rezai M, Kolotas C et al (1989) Tumor-specific immediate reconstruction (TSIR) in breast cancer patients. Perspect Plast Surg 11:71–106 Audretsch W, Rezai M, Kolotas C et al (1989) Tumor-specific immediate reconstruction (TSIR) in breast cancer patients. Perspect Plast Surg 11:71–106
Metadaten
Titel
Long-term outcome after neoadjuvant radiochemotherapy in locally advanced noninflammatory breast cancer and predictive factors for a pathologic complete remission
Results of a multivariate analysis
verfasst von
C. Matuschek
PD Dr. E. Bölke
S.L. Roth
K. Orth
I. Lang
H. Bojar
J.W. Janni
W. Audretsch
C. Nestle-Kraemling
G. Lammering
V. Speer
S. Gripp
P.A. Gerber
B.A. Buhren
R. Sauer
M. Peiper
M. Schauer
M. Dommach
K. Struse-Soll
W. Budach
Publikationsdatum
01.09.2012
Verlag
Springer-Verlag
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 9/2012
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-012-0162-8

Weitere Artikel der Ausgabe 9/2012

Strahlentherapie und Onkologie 9/2012 Zur Ausgabe

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.